Single-agent FAP inhibitor Val-boroPro (Talabostat) had minimal activity in patients with previously treated metastatic colorectal cancer in a phase II trial, despite significant, but incomplete inhibition of FAP enzymatic activity in the peripheral blood [585]. This evidence concerns the gene FAP and metastatic colorectal cancer.